Cargando…

Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study

PURPOSE: mTOR inhibitor everolimus is used for hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (mBC). No reliable predictive biomarker of response is available. Following evidences from other solid tumors, we aimed to assess the association between treatment-associated immune...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schettini, Francesco, Sobhani, Navid, Ianza, Anna, Triulzi, Tiziana, Molteni, Alfredo, Lazzari, Maria Chiara, Strina, Carla, Milani, Manuela, Corona, Silvia Paola, Sirico, Marianna, Bernocchi, Ottavia, Giudici, Fabiola, Cappelletti, Maria Rosaria, Ciruelos, Eva, Jerusalem, Guy, Loi, Sherine, Fox, Stephen B., Generali, Daniele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599144/ https://www.ncbi.nlm.nih.gov/pubmed/32770287 http://dx.doi.org/10.1007/s10549-020-05856-3

Ejemplares similares

Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study
por: Corona, Silvia P., et al.
Publicado: (2020)

Addendum: Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study
por: Corona, Silvia P., et al.
Publicado: (2022)

Early Changes of the Standardized Uptake Values (SUV(max)) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
por: Sirico, Marianna, et al.
Publicado: (2020)

Role of the IGF-1 Axis in Overcoming Resistance in Breast Cancer
por: Ianza, Anna, et al.
Publicado: (2021)

Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature
por: Bernocchi, Ottavia, et al.
Publicado: (2021)

Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial
por: Schettini, Francesco, et al.
Publicado: (2021)

Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2− Breast Cancer Based on a Window of Opportunity Study
por: D’Angelo, Alberto, et al.
Publicado: (2022)

Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2019)

Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2018)

Circulating cell-free nucleic acids as prognostic and therapy predictive tools for metastatic castrate-resistant prostate cancer
por: Sobhani, Navid, et al.
Publicado: (2020)

Would the combination of everolimus with endocrine-therapy help in FGFR2 positive serous endometrial cancer?
por: Cappelletti, Maria Rosa, et al.
Publicado: (2015)

Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma
por: Sobhani, Navid, et al.
Publicado: (2017)

Epithelioid Mesothelioma Patients with Very Long Survival Display Defects in DNA Repair
por: Ganzinelli, Monica, et al.
Publicado: (2023)

Safety, Efficacy, and Patient Acceptability of Everolimus in the Treatment of Breast Cancer
por: Lousberg, Laurence, et al.
Publicado: (2017)

Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study
por: Generali, Daniele, et al.
Publicado: (2021)

PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy
por: Sobhani, Navid, et al.
Publicado: (2017)

The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study
por: Roviello, Giandomenico, et al.
Publicado: (2019)

Computational reactive–diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib
por: Schettini, Francesco, et al.
Publicado: (2023)

Circulating tumor cells correlate with patterns of recurrence in patients with hormone-sensitive prostate cancer
por: Roviello, Giandomenico, et al.
Publicado: (2017)

EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience
por: Ianza, Anna, et al.
Publicado: (2021)

Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer
por: Milani, Manuela, et al.
Publicado: (2017)

Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer
por: Pascual, Tomas, et al.
Publicado: (2017)

Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer
por: Sobhani, Navid, et al.
Publicado: (2018)

Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2021)

FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo
por: Cejka, D, et al.
Publicado: (2009)

Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma
por: D’Angelo, Alberto, et al.
Publicado: (2019)

The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments
por: Sobhani, Navid, et al.
Publicado: (2020)

Advances in anti-BRAF therapies for lung cancer
por: Roviello, Giandomenico, et al.
Publicado: (2021)

An update on antibody–drug conjugates in urothelial carcinoma: state of the art strategies and what comes next
por: D’Angelo, Alberto, et al.
Publicado: (2022)

Mutant p53 as an Antigen in Cancer Immunotherapy
por: Sobhani, Navid, et al.
Publicado: (2020)

CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
por: Sobhani, Navid, et al.
Publicado: (2021)

p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis
por: Sobhani, Navid, et al.
Publicado: (2021)

A Case–Control Study by ddPCR of ALU 260/111 and LINE-1 266/97 Copy Number Ratio in Circulating Cell-Free DNA in Plasma Revealed LINE-1 266/97 as a Potential Biomarker for Early Breast Cancer Detection
por: Bortul, Marina, et al.
Publicado: (2023)

Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy
por: Koukourakis, M I, et al.
Publicado: (2014)

Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit
por: Triulzi, Tiziana, et al.
Publicado: (2018)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer
por: Allevi, G, et al.
Publicado: (2013)

Vorolanib and everolimus: Lenvatinib and everolimus part deux, or something new?
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2020)

AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption
por: Sobhani, Navid, et al.
Publicado: (2021)

Predictive and Prognostic Value of Non-Coding RNA in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2022)

Intermittent everolimus administration for malignant insulinoma
por: Baratelli, Chiara, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_3n805ic7vi9qb10un73c028cnd